ArticleJournal of lipid and atherosclerosis2026
Cardiovascular Disease Incidence and Lipid-Lowering Medication Use in Korean Adults With Dyslipidemia: A Nationwide Population-Based Retrospective Cohort Study From 2010 to 2019.
Article in Journal of lipid and atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Dyslipidemia is a major modifiable risk factor for cardiovascular disease (CVD). We investigated temporal trends in CVD incidence and lipid-lowering therapy in individuals with dyslipidemia. Methods: We conducted a nationwide population-based retrospective cohort study using the Korean National Health Insurance Service-National Sample Cohort (2010-2019) to assess age- and sex-standardized incidence rates of overall CVD, including ischemic heart disease, ischemic stroke, and heart failure, among adults aged ≥20 years. Dyslipidemia was identified based on the International Classification of Diseases, 10th Revision code E78 and/or the use of lipid-lowering agents. Prescription patterns for statins categorized by intensity, fibrates, and ezetimibe were analyzed. Results: The overall age-standardized incidence of CVD among individuals with dyslipidemia declined markedly from 36.9 to 20.9 per 1,000 person-years. This downward trend was largely driven by substantial reductions in ischemic heart disease (from 29.2 to 15.0; a 48.6% decrease) and ischemic stroke (from 12.5 to 6.6; a 47.2% decrease). Meanwhile, the incidence of heart failure increased slightly, rising from 6.4 to 8.5 per 1,000 person-years. Statin use reached 95.3% by 2019 among dyslipidemic patients, but high-intensity statin use remained limited (4.7% of statin users). Ezetimibe use increased approximately four-fold, while fibrate use remained relatively unchanged. Conclusion: CVD incidence declined substantially in the dyslipidemic population over the past decade. During the study period, lipid-lowering treatment patterns were characterized by widespread statin use and a substantial increase in ezetimibe prescriptions, although the use of high-intensity statins remained persistently low. These findings highlight opportunities to further optimize lipid-lowering strategies in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.